Literature DB >> 28187515

Erythroferrone and matriptase-2 independently regulate hepcidin expression.

Sharraya Aschemeyer1,2, Victoria Gabayan1, Tomas Ganz1,3, Elizabeta Nemeth1, Léon Kautz4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28187515      PMCID： PMC5389904          DOI： 10.1002/ajh.24672

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

1.  Erythroferrone contributes to hepcidin suppression and iron overload in a mouse model of β-thalassemia.

Authors:  Léon Kautz; Grace Jung; Xin Du; Victoria Gabayan; Justin Chapman; Marc Nasoff; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2015-08-14       Impact factor: 22.113

2.  Is EPO therapy able to correct iron deficiency anaemia caused by matriptase-2 deficiency?

Authors:  Gaël Nicolas; Jean-Christophe Deschemin; Andrew J Ramsay; Patrick Mayeux; Bernard Grandchamp; Carole Beaumont; Gloria Velasco; Sophie Vaulont
Journal:  Br J Haematol       Date:  2011-01-11       Impact factor: 6.998

Review 3.  Iron refractory iron deficiency anemia.

Authors:  Luigia De Falco; Mayka Sanchez; Laura Silvestri; Caroline Kannengiesser; Martina U Muckenthaler; Achille Iolascon; Laurent Gouya; Clara Camaschella; Carole Beaumont
Journal:  Haematologica       Date:  2013-06       Impact factor: 9.941

4.  Erythroferrone contributes to recovery from anemia of inflammation.

Authors:  Léon Kautz; Grace Jung; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2014-09-05       Impact factor: 22.113

5.  Limiting hepatic Bmp-Smad signaling by matriptase-2 is required for erythropoietin-mediated hepcidin suppression in mice.

Authors:  Antonella Nai; Aude Rubio; Alessandro Campanella; Ophélie Gourbeyre; Irene Artuso; Jessica Bordini; Aurélie Gineste; Chloé Latour; Céline Besson-Fournier; Herbert Y Lin; Hélène Coppin; Marie-Paule Roth; Clara Camaschella; Laura Silvestri; Delphine Meynard
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

6.  Identification of erythroferrone as an erythroid regulator of iron metabolism.

Authors:  Léon Kautz; Grace Jung; Erika V Valore; Stefano Rivella; Elizabeta Nemeth; Tomas Ganz
Journal:  Nat Genet       Date:  2014-06-01       Impact factor: 38.330
  6 in total
  13 in total

1.  Protein Modifications Critical for Myonectin/Erythroferrone Secretion and Oligomer Assembly.

Authors:  Ashley N Stewart; Hannah C Little; David J Clark; Hui Zhang; G William Wong
Journal:  Biochemistry       Date:  2020-07-06       Impact factor: 3.162

Review 2.  Liver iron sensing and body iron homeostasis.

Authors:  Chia-Yu Wang; Jodie L Babitt
Journal:  Blood       Date:  2018-11-06       Impact factor: 22.113

3.  Genetic loss of Tmprss6 alters terminal erythroid differentiation in a mouse model of β-thalassemia intermedia.

Authors:  David B Stagg; Rebecca L Whittlesey; Xiuqi Li; Larisa Lozovatsky; Sara Gardenghi; Stefano Rivella; Karin E Finberg
Journal:  Haematologica       Date:  2019-02-28       Impact factor: 9.941

4.  Bitopertin, a selective oral GLYT1 inhibitor, improves anemia in a mouse model of β-thalassemia.

Authors:  Alessandro Matte; Enrica Federti; Michael Winter; Annette Koerner; Anja Harmeier; Norman Mazer; Tomas Tomka; Maria Luisa Di Paolo; Luigia De Falco; Immacolata Andolfo; Elisabetta Beneduce; Achille Iolascon; Alejandra Macias-Garcia; Jane-Jane Chen; Anne Janin; Christhophe Lebouef; Franco Turrini; Carlo Brugnara; Lucia De Franceschi
Journal:  JCI Insight       Date:  2019-11-14

5.  Smad1/5 is required for erythropoietin-mediated suppression of hepcidin in mice.

Authors:  Chia-Yu Wang; Amanda B Core; Susanna Canali; Kimberly B Zumbrennen-Bullough; Sinan Ozer; Lieve Umans; An Zwijsen; Jodie L Babitt
Journal:  Blood       Date:  2017-04-24       Impact factor: 22.113

6.  Erythroferrone inhibits the induction of hepcidin by BMP6.

Authors:  João Arezes; Niall Foy; Kirsty McHugh; Anagha Sawant; Doris Quinkert; Virginie Terraube; Alette Brinth; May Tam; Edward R LaVallie; Stephen Taylor; Andrew E Armitage; Sant-Rayn Pasricha; Orla Cunningham; Matthew Lambert; Simon J Draper; Reema Jasuja; Hal Drakesmith
Journal:  Blood       Date:  2018-08-10       Impact factor: 22.113

7.  Serum Erythroferrone During Pregnancy Is Related to Erythropoietin but Does Not Predict the Risk of Anemia.

Authors:  Katherine M Delaney; Ronnie Guillet; Eva K Pressman; Tomas Ganz; Elizabeta Nemeth; Kimberly O O'Brien
Journal:  J Nutr       Date:  2021-07-01       Impact factor: 4.687

Review 8.  Erythroferrone structure, function, and physiology: Iron homeostasis and beyond.

Authors:  Daniel N Srole; Tomas Ganz
Journal:  J Cell Physiol       Date:  2020-12-28       Impact factor: 6.513

9.  Antibodies against the erythroferrone N-terminal domain prevent hepcidin suppression and ameliorate murine thalassemia.

Authors:  João Arezes; Niall Foy; Kirsty McHugh; Doris Quinkert; Susan Benard; Anagha Sawant; Joe N Frost; Andrew E Armitage; Sant-Rayn Pasricha; Pei Jin Lim; May S Tam; Edward Lavallie; Debra D Pittman; Orla Cunningham; Matthew Lambert; John E Murphy; Simon J Draper; Reema Jasuja; Hal Drakesmith
Journal:  Blood       Date:  2020-02-20       Impact factor: 25.476

Review 10.  Treatment of renal anemia: Erythropoiesis stimulating agents and beyond.

Authors:  Patrick Biggar; Gheun-Ho Kim
Journal:  Kidney Res Clin Pract       Date:  2017-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.